Lepu Biopharma Co Ltd
Company Profile
Business description
Lepu Biopharma Co Ltd is a biopharmaceutical company focusing on oncology therapeutics and has one operating segment. The Group is principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The majority operating entity of the Group is domiciled in Mainland China. The company has established an integrated end-to-end platform across drug discovery, clinical development, CMC, and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain. The company generates the majority of its revenue from the Sale of pharmaceutical products. The company also generates a small portion of its revenue from Licensing income.
Contact
No. 651, Lianheng Road
Minhang District
Shanghai201112
CHNT: +86 2167680899
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
710
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
stocks
World’s largest miner overvalued after solid quarter
stocks
Hidden value in an expensive ASX
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,024.20 | 27.20 | -0.30% |
| CAC 40 | 8,227.32 | 70.89 | 0.87% |
| DAX 40 | 24,180.68 | 14.22 | -0.06% |
| Dow JONES (US) | 49,450.61 | 39.42 | -0.08% |
| FTSE 100 | 10,457.01 | 19.45 | -0.19% |
| HKSE | 25,915.20 | 248.04 | -0.95% |
| NASDAQ | 24,625.42 | 32.15 | -0.13% |
| Nikkei 225 | 59,140.23 | 445.63 | -0.75% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,141.46 | 3.56 | 0.05% |
| S&P/ASX 200 | 8,793.40 | 26.10 | -0.30% |
| SSE Composite Index | 4,093.25 | 13.01 | -0.32% |